Home

News

Charlotte May gives keynote address at the SPC Workshop in Munich20 March 2017Charlotte May QC was invited to give the keynote address at the SPC Workshop in Munich, organised by the Max Planck Institute in collaboration with the German Patent Office. The Workshop was attended by lawyers, patent attorneys, industry specialists and national patent office representatives from across Europe and involved a stimulating debate about all aspects […]
8 New Square awarded UK IP Set of the year at the MIP awards dinner10 March 2017For the second year running, 8 New Square were awarded the UK IP Set of the year by the Managing Intellectual Property Global publication at an awards dinner in the Savoy Hotel in London on 9th March. James Abrahams QC accompanied by Martin Williams collected the award.
8 New Square awarded UK IP Set of the year at the MIP awards dinner10 March 2017 For the second year running, 8 New Square were awarded the UK IP Set of the year by the Managing Intellectual Property Global publication at an awards dinner in the Savoy Hotel in London on 9th March. James Abrahams QC accompanied by Martin Williams collected the award.
Fujifilm Kyowa Kirin Biologics Company v Abbvie Biotechnology and Others3 March 2017Michael Tappin QC, Andrew Lykiardopoulos QC and Mark Chacksfield appeared for the Defendant (“AbbVie”) in this action concerning certain of AbbVie’s patents and applications for the anti-inflammatory drug adalimumab (marketed by AbbVie as “Humira”). The Claimants (“FKB” and “SB/Biogen”) sought declarations (the “Declarations”) to the effect that use of their biosimilar adalimumab products in certain […]
Argos Ltd v Argos Systems Inc [2017] EWHC 231 (Ch)15 February 2017Three members of chambers acted in a substantial trade mark infringement and passing off dispute between the British retailer, Argos Ltd (‘Argos UK’), and an American software company, Argos Systems Inc. The claim concerned the defendant’s use of the sign ARGOS in its domain name www.argos.com and on its website, on which it had placed […]
Wobben v Siemens [2017] EWCA Civ 519 January 2017James Whyte represented the Respondents (collectively “Siemens”) in this appeal concerning Wobben’s patent for a method of operation of a wind turbine in high winds. At first instance Birss J had found that Wobben’s patent was obvious in light of a prior art research paper “Bossanyi”, which disclosed strategies to mitigate the effects of wind […]
Wobben Properties GMBH v Siemens PLC & Others19 January 2017James Whyte represented the Respondents (collectively “Siemens”) in this appeal concerning Wobben’s patent for a method of operation of a wind turbine in high winds. At first instance Birss J had found that Wobben’s patent was obvious in light of a prior art research paper “Bossanyi”, which disclosed strategies to mitigate the effects of wind […]
Shanks v Unilever [2017] EWCA Civ 218 January 2017In Shanks v Unilever, the Court of Appeal dismissed Prof Shanks’ second tier appeal against the IPO’s rejection of his multi-million pound claim under s.40(1) of the Patents Act 1977 for inventor’s compensation against his former employer, Unilever, in respect of patents which he claimed to be of ‘outstanding benefit’ to Unilever. The patents were […]
Shanks -v- Unilever18 January 2017In Shanks v Unilever [2017] EWCA Civ 2, the Court of Appeal dismissed Prof Shanks’ second tier appeal against the IPO’s rejection of his multi-million pound claim under s.40(1) of the Patents Act 1977 for inventor’s compensation against his former employer, Unilever, in respect of patents which he claimed to be of ‘outstanding benefit’ to […]
Teva, Accord, Lupin, Generics (UK) t/a Mylan v Gilead [2017] EWHC 13 (Pat)13 January 2017Daniel Alexander QC and Lindsay Lane appeared for one claimant (Teva), Daniel Alexander QC and Jaani Riordan appeared for another claimant (Lupin), and James Whyte appeared for the defendant (Gilead), in these actions concerning Gilead’s Supplementary Protection Certificate (SPC) for an anti-retroviral drug combining tenofovir disoproxil and emtricibatine (marketed by Gilead as ‘Truvada’). The claimants […]